Reduced-intensity hematopoietic stem cell transplants for malignancies: Harnessing the graft-versus-tumor effect

Annual Review of Medicine

Volumn 64, Issue , 2013, Pages 101-117

  Gill, Saar ^a   Porter, David L ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

bone marrow transplantation; immunotherapy; nonmyeloablative transplantation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN; PROTEIN TYROSINE KINASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AGGRESSIVE B CELL NON HODGKIN LYMPHOMA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CELL THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DISEASE SEVERITY; ENGRAFTMENT; FOLLICULAR NON HODGKIN LYMPHOMA; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IMMUNE SYSTEM; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NONHODGKIN LYMPHOMA; PATIENT SAFETY; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REMISSION; RISK ASSESSMENT; T CELL DEPLETION; T CELL NON HODGKIN LYMPHOMA; WHOLE BODY RADIATION;

ANIMALS; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASMS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84873046473     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-121411-103452     Document Type: Article

References (100)

1. Niederwieser D, MarisM, Shizuru JA, et al. 2003. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101(4):1620-29
2. Lowsky R, Takahashi T, Liu YP, et al. 2005. Protective conditioning for acute graft-versus-host disease. N. Engl. J. Med. 353(13):1321-31
3. Porter D, Roth M, McGarigle C, et al. 1994. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N. Engl. J. Med. 330:100-6
4. Storb RF, Champlin R, Riddell SR, et al. 2001. Non-myeloablative transplants for malignant disease. Hematol. Am. Soc. Hematol. Educ. Program 2001:375-91
5. Giralt S, Ballen K, Rizzo D, et al. 2009. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow transplant research. Biol. Blood Marrow Transplant. 15(3):367-69
6. Hegenbart U, Niederwieser D, Sandmaier BM, et al. 2006. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J. Clin. Oncol. 24(3):444-53
7. Ringdén O, Labopin M, Ehninger G, et al. 2009. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J. Clin. Oncol. 27(27):4570-77
8. Bornhauser M, Kienast J, Trenschel R, et al. 2011. An intergroup randomised trial of standard intensity versus reduced intensityTBI-based conditioning in patients with acute myeloid leukemia in first complete remission. Am. Soc. Hematol. Annu. Meet. Abstr. 118:Abstr. 157
9. Luger SM, Ringdén O, Zhang M-J, et al. 2012. Similar outcomes using myeloablative versus reducedintensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant. 47(2):203-11
10. Maris MB, Niederwieser D, Sandmaier BM, et al. 2003. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 102(6):2021-30
11. Girgis M, Hallemeier C, Blum W, et al. 2005. Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide. Blood 105(8):3035-41
12. Soiffer RJ, Lerademacher J, Ho V, et al. 2011. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 117(25):6963-70
13. de Lima M, Anagnostopoulos A, Munsell M, et al. 2004. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104(3):865-72
14. Shimoni A, Hardan I, Shem-Tov N, et al. 2007. Comparison between two fludarabine-based reducedintensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: Fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan. Leukemia 21(10):2109-16
15. Sayer HG, Kröger M, Beyer J, et al. 2003. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant. 31(12):1089-95
16. van Besien K, Artz A, Smith S, et al. 2005. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J. Clin. Oncol. 23(24):5728-38
17. Loren AW, Luger SM, Stadtmauer EA, et al. 2005. Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation. Bone Marrow Transplant. 35(9):921-26
18. Ferrara JL, Antin JH. 2007. The pathophysiology of graft-versus-host disease. In Thomas' Hematopoietic Cell Transplantation, ed. FR Appelbaum, SJ Forman, RS Negrin, KG Blume, pp. 208-21. Chichester, UK:Wiley-Blackwell. 4th ed.
19. Couriel DR, Saliba RM, Giralt S, et al. 2004. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol. Blood Marrow Transplant. 10(3):178-85
20. Aoudjhane M, Labopin M, Gorin NC, et al. 2005. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey. Leukemia 19(12):2304-12
21. Weissinger F. 2001. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 98(13):3584-88
22. Junghanss C, Marr KA, Carter RA, et al. 2002. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol. Blood Marrow Transplant. 8(9):512-20
23. Fukuda T, Hackman RC, Guthrie KA, et al. 2003. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 102(8):2777-85
24. HoganWJ, MarisM, Storer B, et al. 2004. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 103(1):78-84
25. Parikh CR, Schrier RW, Storer B, et al. 2005. Comparison of ARF aftermyeloablative and nonmyeloablative hematopoietic cell transplantation. Am. J. Kidney Dis. 45(3):502-9
26. Junghanss C. 2002. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 99(6):1978-85
27. Kahl C, Storer BE, Sandmaier BM, et al. 2007. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 10(7):2744-48
28. Horowitz MM, Gale RP, Sondel PM, et al. 1990. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75(3):555-62
29. Kolb HJ, Schattenberg A, Goldman JM, et al. 1995. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86(5):2041-50
30. van Besien K, Artz A, Smith S, et al. 2005. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J. Clin. Oncol. 23(24):5728-38
31. McClune BL, Weisdorf DJ, Pedersen TL, et al. 2010. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J. Clin. Oncol. 28(11):1878-87
32. Schmid C, Labopin M, Nagler A, et al. 2012. Treatment, risk factors, and outcome of adults with relapsed AMLafter reduced intensity conditioning for allogeneic stem cell transplantation. Blood 119(6):1599-606
33. Lioure B, BénéMC, Pigneux A, et al. 2012. Early matched sibling hematopoietic cell transplantation for adultAMLin first remission using an age-adapted strategy: long-term results of a prospectiveGOELAMS study. Blood 119(12):2943-48
34. Stelljes M, Bornhauser M, Kroger M, et al. 2005. Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Blood 106(9):3314-21
35. Shaw BE, Mufti GJ, Mackinnon S, et al. 2008. Outcome of second allogeneic transplants using reducedintensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant. 42(12):783-89
36. Schanz J, Tüchler H, Solé F, et al. 2012. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J. Clin. Oncol. 30(8):820-29
37. Greenberg P, Cox C, LeBeau MM, et al. 1997. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6):2079-88
38. Cutler CS, Lee SJ, Greenberg P, et al. 2004.Adecision analysis of allogeneic bonemarrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104(2):579-85
39. Alessandrino EP, Della Porta MG, Bacigalupo A, et al. 2008. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 112(3):895-902
40. Cutler C. 2010. Allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndrome. Hematol. Am. Soc. Hematol. Educ. Program 2010:325-29
41. ChangC, Storer BE, Scott BL, et al. 2007. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 110(4):1379-87
42. Nevill TJ, Fung HC, Shepherd JD, et al. 1998. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 92(6):1910-17
43. Lim Z, Brand R, Martino R, et al. 2010. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J. Clin. Oncol. 28(3):405-11
44. De Padua Silva L, de Lima M, Kantarjian H, et al. 2009. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant. 43(11):839-43
45. Field T, Perkins J, Huang Y, et al. 2010. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 45(2):255-60
46. Taussig DC, Davies AJ, Cavenagh JD, et al. 2003. Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. J. Clin. Oncol. 21(16):3060-65
47. Martino R, Iacobelli S, Brand R, et al. 2006. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108(3):836-46
48. Shimoni A, Hardan I, Shem-Tov N, et al. 2006. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 20(2):322-28
49. Laport GG, Sandmaier BM, Storer BE, et al. 2008. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol. Blood Marrow Transplant. 14(2):246-55
50. Warlick E, Ahn KW, Pedersen TL, et al. 2012. RIC is superior to NMA conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the TKI era. Blood 119:4083-90
51. Kröger N, Holler E, Kobbe G, et al. 2009. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 114(26):5264-70
52. Benjamini O, Koren-MichowitzM, Amariglio N, et al. 2008. Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitativePCRtest forV617F-JAK2mutation. Leukemia 22(10):1961-63
53. Goldstone AH, Richards SM, Lazarus HM, et al. 2008. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation. Blood 111(4):1827-33
54. Marks DI, Wang T, Pérez WS, et al. 2010. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosomenegative acute lymphoblastic leukemia in first and second complete remission. Blood 116(3):366-74
55. Mohty M, Labopin M, Volin L, et al. 2010. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 116(22):4439-43
56. Marks DI, Lush R, Cavenagh J, et al. 2002. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 100(9):3108-14
57. Gribben JG, Zahrieh D, Stephans K, et al. 2005. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 106(13):4389-96
58. Dreger P, DöhnerH, RitgenM, et al. 2010. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 116(14):2438-47
59. Sorror ML, Storer BE, Sandmaier BM, et al. 2008. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J. Clin. Oncol. 26(30):4912-20
60. Hari P, Carreras J, Zhang M-J, et al. 2008. Allogeneic transplants in follicular lymphoma: Higher risk of disease progression after reduced intensity compared to myeloablative conditioning. Biol. Blood Marrow Transplant 14(2):236-45
61. Tomblyn M, Brunstein C, Burns LJ, et al. 2008. Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 14(5):538-45
62. Armand P, KimHT, Ho VT, et al. 2008. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol. Blood Marrow Transplant 14(4):418-25
63. Rezvani AR, Storer B, Maris M, et al. 2008. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 26(2):211-17
64. Thomson KJ, Morris EC, Milligan D, et al. 2010. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J. Clin. Oncol. 28(23):3695-700
65. Khouri IF, McLaughlin P, Saliba RM, et al. 2008. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111(12):5530-36
66. Piñana JL, Martino R, Gayoso J, et al. 2010. Reduced intensity conditioningHLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica 95(7):1176-82
67. Robinson SP, Goldstone AH, Mackinnon S, et al. 2002. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the LymphomaWorking Party of the European Group for Blood and BoneMarrow Transplantation. Blood 100(13):4310-16
68. Sorror ML, Storer BE, Maloney DG, et al. 2008. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 111(1):446-52
69. Van Kampen R, Canals C, Schouten H, et al. 2011. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J. Clin. Oncol. 29(10):1342-48
70. Thomson KJ, Morris EC, Bloor A, et al. 2009. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 27(3):426-32
71. Rezvani AR, Norasetthada L, Gooley T, et al. 2008. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br. J. Haematol. 143(3):395-403
72. Khouri IF, Lee M-S, Saliba RM, et al. 2003. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J. Clin. Oncol. 21(23):4407-12
73. Le Gouill S, Milpied N, Buzyn A, et al. 2008. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J. Clin. Oncol. 26(14):2264-71
74. Kyriakou C, Canals C, Finke J, et al. 2009. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblasticT- cell lymphoma: a retrospective study from theLymphomaWorking Party of the European Group for Blood and Marrow Transplantation. J. Clin. Oncol. 27(24):3951-58
75. Alvarez I, Sureda A, Caballero MD, et al. 2006. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol. Blood Marrow Transplant. 12(2):172-83
76. Sarina B, Castagna L, Farina L, et al. 2010. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 115(18):3671-77
77. Thomson KJ, Peggs KS, Smith P, et al. 2008. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant. 41(9):765-70
78. Sureda A, Robinson S, Canals C, et al. 2008. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J. Clin. Oncol. 26(3):455-62
79. Peggs KS, Kayani I, Edwards N, et al. 2011. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J. Clin. Oncol. 29(8):971-78
80. Corradini P, Sarina B, Farina L. 2011. Allogeneic transplantation for Hodgkin's lymphoma. Br. J. Haematol. 152(3):261-72
81. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. 2000. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and longterm outcome. J. Clin. Oncol. 18(16):3031-37
82. LokhorstHM, WuK, Verdonck LF, et al. 2004. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions inmultiplemyeloma. Blood 103(11):4362-64
83. Bruno B, Rotta M, Patriarca F, et al. 2007. A comparison of allografting with autografting for newly diagnosed myeloma. N. Engl. J. Med. 356(11):1110-20
84. Crawley C, Iacobelli S, Björkstrand B, et al. 2007. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 109(8):3588-94
85. Crawley C, Lalancette M, Szydlo R, et al. 2005. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 105(11):4532-39
86. Garban F, Attal M, Michallet M, et al. 2006. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 107(9):3474-80
87. Rosiñol L, Pérez-Simón JA, Sureda A, et al. 2008. A prospectivePETHEMAstudy of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 112(9):3591-93
88. Krishnan A, Pasquini MC, Logan B, et al. 2011. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 12(13):1195-203
89. Björkstrand B, Iacobelli S, HegenbartU, et al. 2011. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J. Clin. Oncol. 29(22):3016-22
90. Kumar SK, Rajkumar SV, Dispenzieri A, et al. 2008. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516-20
91. Lokhorst H, Einsele H, Vesole D, et al. 2010. InternationalMyeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J. Clin. Oncol. 28(29):4521-30
92. Bethge WA, Hegenbart U, Stuart MJ, et al. 2004. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 103(3):790-95
93. Oran B, Giralt S, Couriel D, et al. 2007. Treatment of AML andMDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 21(12):2540-44
94. Delgado J, Thomson K, Russell N, et al. 2006. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood 107(4):1724-30
95. Ritgen M, Stilgenbauer S, von Neuhoff N, et al. 2004. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavychain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 104(8):2600-2
96. van de Donk NWCJ, Kröger N, Hegenbart U, et al. 2006. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant. 37(12):1135-41
97. Peggs KS, Thomson K, Hart DP, et al. 2004. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 103(4):1548-56
98. Mohamedbhai SG, Edwards N, Morris EC, et al. 2012. Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure. Br. J. Haematol. 156(4):516-22
99. Platzbecker U, Wermke M, Radke J, et al. 2011. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 26:381-89
100. Porter DL, Levine BL, Kalos M, et al. 2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365(8):725-33